… notorious GlaxoSmithKline enabler Professor Martin Keller, now tries its hand at legitimate research in the form of an article that actually cautions against polypharmacy.
[B]ecause no clinical trial of bipolar medications has ever tested more than two drugs in combination, prescribing three or four exceeds practices supported by the field.
“By definition that’s not evidence-based treatment,” [the article’s lead author] said.
No prior studies had looked at the total medication burden, rather than just that of pyschotropics. It’s important to do so, Weinstock said, because cardiometabolic diseases, in particular, are often concurrent with bipolar disorder. Among the 230 patients in the study, for example, about half had such medical problems.
… “[The] increased reliance on polypharmacy does not appear to be contributing to decreased rates of illness chronicity or functional impairment in [bipolar disorder].”
I guess Brown faculty can do market-depressant research now that Keller (he was a honcho) has retired.